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bophlebitis, severe varicosities, or prior coronary
bypass operations, an increasing number of patients
requiring coronary bypass operations do not have suffi-
cient bypass material of their own for coronary revas-
cularization. It is estimated that up to 20% of all
patients requiring coronary bypass fall into this catego-
ry.1 If complete arterial coronary artery revasculariza-
tion can be achieved by using the internal thoracic
artery (ITA), the radial artery as a free graft, or the gas-
troepiploic artery, this is the method of first choice,
despite the increased incidence for some relevant com-
plications (eg, postoperative ischemia of the hand after
using the radial artery for coronary bypass is report-
ed).2,3 Our intention was to increase the biocompatibil-
ity of commercially available expanded 4-mm polyte-
trafluoroethylene (PTFE) vascular grafts by seeding the
luminal wall of the graft with vital autologous endothe-
P atients with symptomatic, multiple-vessel coronaryartery disease often need bypass operations for
coronary revascularization. Because of previous throm-
Objective: Autologous endothelial cell seeding was used to improve the
patency of 4-mm polytetrafluoroethylene vascular prostheses.
Methods: Since 1995, 14 patients with coronary artery disease received 21
autologous endothelial cell–seeded polytetrafluoroethylene vascular bypass
grafts for coronary artery revascularization. The polytetrafluoroethylene
grafts were seeded with the endothelial cells in a multiple step procedure,
including cell culture techniques before coronary bypass operation. With the
use of extracorporal circulation and cardioplegic arrest, a bypass operation
was performed by means of conventional surgical techniques.
Results: After a mean postoperative follow-up of 27.7 months (range, 7.5-48
months), the graft patency rate is 90.5%. Follow-up angiograms of the aorta-
coronary polytetrafluoroethylene bypass grafts showed patent bypasses in all
cases except two. Angiograms of all 19 patent endothelial cell–seeded poly-
tetrafluoroethylene bypass grafts showed a smooth luminal borderline with-
out stenotic regions. The percutaneous transluminal angioscopic evaluation
showed a glossy white and smooth endoluminal graft surface without any
fibrin, platelet, or erythrocyte deposits. Intravascular ultrasonographic exam-
inations confirmed the results.
Conclusion: Patency of autologous endothelial cell–seeded 4-mm polytetra-
fluoroethylene vascular prostheses as coronary artery bypass grafts was much
better than that of unseeded polytetrafluoroethylene grafts. Further evalua-
tions and a larger population of patients will prove whether the encouraging
patency will last.  (J Thorac Cardiovasc Surg 2000;120:134-41)
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lial cells (ECs) from cell cultures, preparing a physio-
logic luminal graft surface by the patient’s own vital
EC monolayer.4,5
Patients and methods
Patient selection. Patients with stable angina pectoris suit-
able for elective coronary artery bypass operations were cho-
sen who had hemodynamically relevant coronary artery
stenosis and in whom complete coronary revascularization
with the ITA and saphenous vein was not possible. The
patients were over 60 years of age. The study protocol was
approved by the local ethics committee of the Humboldt
University, and informed documented consent was obtained
from all patients before the bypass procedure.
Graft preparation
Harvest of the autologous ECs. After achievement of local
anesthesia, a 5- to 10-cm long segment of a cutaneous vein
(eg, forearm or neck) of the patient was removed atraumati-
cally, occluding all side branches with 5-0 ligatures.
Simultaneously, 200 mL of the patient’s blood was taken to
prepare approximately 100 mL of serum.
The removed segment of the vein was immediately rinsed
with Dulbecco’s modified Eagle’s medium (DMEM, Sigma
Chemical Co, St Louis, Mo) to wash out all remaining blood
particles. The lumen of the vein was filled with 0.2% colla-
genase P (Boehringer Ingelheim Pharmaceuticals, Inc.,
Ridgefield, Conn) to remove the ECs, both ends of the vein
being occluded with a stopcock. An incubation for 30 minutes
followed under cell culture conditions (37°C/5% CO2/satu-
rated humidified air). The luminal liquid with the suspended
ECs was then collected and centrifuged at 500g for 10 min-
utes. The pellet containing the ECs was resuspended in
DMEM plus 20% autologous patient serum.
EC culture. The resuspended pellet of the ECs was seeded
in cell culture flasks (12.5 cm2) in DMEM plus 20% autolo-
gous serum enriched with 5 ng/mL human recombinant basic
fibroblast growth factor (hbFGF) carrier free (Boehringer).6,7
Under cell culture conditions, the ECs were cultured until
reaching confluency, changing the culture medium every 48
hours. The confluent cell layer was tested for homogeneity of
the ECs by means of anti-factor VIII–conjugated monoclonal
antibodies (MAB) (Sigma, Fig 1), a specific test for ECs to
exclude a contamination of the cell culture by fibroblasts. The
vitality of the ECs was tested with trypan blue (Sigma). After
2 passages of subculturing (time period, 4-6 weeks), enough
ECs could be achieved to cover the luminal surface of a 20-
cm long PTFE graft that was 4 mm in diameter, with a con-
fluent EC monolayer (seeding density, 6 × 104 EC/cm2).
Precoating of the PTFE graft with a fibrin matrix.
Commercially available sterile expanded PTFE vascular
grafts of 4 mm in diameter*† were cut into 20-cm long seg-
ments. The luminal surface of the graft was coated with
modified two-component fibrin glue (Tissucol; Immuno,
Olivos, Buenos Aires, Brazil), including 5 ng/mL hbFGF
(Boehringer). Fibrin and bFGF both support EC adhesion,
spreading, migration, and proliferation.8-11 Finally, the
luminal surface of the graft was smoothed by pulling
through an inflated balloon of a small Fogarty catheter to
remove excessive fibrin glue.
EC seeding of the PTFE graft. ECs of confluent cultures
were harvested with the use of 0.2% collagenase P and count-
ed and diluted with DMEM to the final volume of the PTFE
graft. The EC suspension was filled into the fibrin-precoated
PTFE graft, occluding both ends with stopcocks. Under cell
culture conditions, the fibrin-precoated PTFE graft was
placed into a special seeding device (Endostrabilisator;
Biegler Medizinelektronik, Mauerbach, Austria). As the graft
was slowly rotated stepwise around its longitudinal axis, the
ECs adhered to the fibrin-coated luminal PTFE graft wall
within 3 hours, with gravity used for the sedimentation of the
ECs. The adherence of the ECs to the luminal wall of the
graft was controlled by counting the cell number of the elu-
ate of the PTFE graft after finishing the seeding procedure
and by electron microscopy of specimens of the graft.12,13
After each step of the coating procedure, 3 swabs were taken
to exclude bacterial or fungal contamination.
Fig 1.  Positive immunohistochemical staining for anti-factor
VIII of human ECs (cephalic vein) from a subconfluent
monolayer in cell culture (dots). (Indirect peroxidase stain-
ing, counterstaining with Mayer’s acid hemalum; original
magnification 200×.)
*Gore-Tex vascular graft, registered trademark of W. L. Gore &
Associates, Inc, Flagstaff, Ariz.
†Mediflex vascular graft; registered trademark of Medino GmbH,
Gehrden, Germany.
Table I.  Patients receiving autologous EC-seeded
PTFE grafts
Postthrombotic syndrome n = 5
Severe varicosis n = 9
ITA already used n = 3
Redo CABG operation n = 6
Age >60 y n = 14
CABG, Coronary artery bypass graft.
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Graft maturation. After the adherence of the ECs to the
luminal graft surface, the graft was stored for 8 to 10 days in
DMEM plus 20% autologous patient serum in an incubator
under cell culture conditions to allow the maturation of the
links between the fibrin-precoated graft luminal surface and
the ECs.14
PTFE graft implantation. A routine coronary artery
bypass procedure was performed with normothermic car-
diopulmonary bypass and intermittent antegrade applica-
tion of Bretschneider cardioplegic solution for cardioplegic
arrest. The EC-seeded PTFE grafts were implanted by per-
forming an end-to-side anastomosis with a running suture
(7-0 Prolene; Ethicon, Inc, Somerville, NJ) between the
coronary artery and the PTFE graft. The central bypass
anastomoses of the PTFE grafts were created to the ascend-
ing aorta in an end-to-side fashion with a running suture (6-
0 Prolene).
Follow-up conditions. Long-term anticoagulation with
dicumarol derivatives was not given to any of the patients
postoperatively. The patients received only 100 mg of acetyl-
salicylic acid per day orally, which was routinely given to all
patients undergoing coronary artery bypass. Every patient
with an EC-seeded PTFE graft as coronary bypass was
checked by selective angiography, angioscopy (Baxter angio-
scope Ø 1.5 mm, tip Ø 1.0 mm; Baxter Healthcare Corp,
Irvine, Calif) and intravascular ultrasonography15 6 and 12
months postoperatively and then annually.
Results
Since September 1995, 14 patients (12 men and 2
women) between 61 and 79 years of age (median, 74
years) with severe symptomatic coronary artery disease
received 21 autologous EC-seeded 4-mm expanded
PTFE vascular bypass grafts for coronary artery revas-
cularization. EC-seeded PTFE grafts were used in
patients who lacked suitable autologous bypass mater-
ial for coronary revascularization and were older than
60 years (Table I). Successful endoluminal seeding of
4-mm PTFE vascular prostheses with a confluent
monolayer of ECs was demonstrated by means of elec-
tron microscopy. The scanning electron microscopy of
a luminal EC-seeded 4-mm PTFE graft 10 days after
EC seeding shows a confluent monolayer of ECs (Fig
2). Transmission electron microscopy of an EC-seeded
PTFE prosthesis demonstrates linked ECs in monolay-
er formation resting on a fibrin matrix (Fig 3). The
demographic data of the patients and the performed
surgical procedures are listed in Table II. The 14
patients received 34 coronary artery bypass grafts. Six
patients had previous bypass operations with occluded
veins or ITA grafts. In 1 patient the aortic valve was
replaced as well because of severe aortic stenosis. For
revascularization of the left anterior descending artery
(LAD), in 10 patients the left ITA was used. Twenty-
one aorta-coronary bypasses were performed with the
EC-seeded PTFE grafts to revascularize the LAD in 1
patient, the first diagonal branch in 3 patients, the
ramus intermedius in 1 patient, the first marginal
Fig 2. Scanning electron microscopy of the luminal surface
of an EC-seeded, fibrin matrix–precoated PTFE graft. ECs
show the typical polygonal pattern. (Original magnification
1260×.)
Fig 3. Transmission electron microscopy of a transverse cut
through the wall of an EC-seeded PTFE graft. ECs with a
nucleus (n) are connected by tight junctions in the intercellu-
lar space (s) and cover the luminal surface of the fibrin-pre-
coated PTFE graft (black border), completely separating the
lumen (i) from the PTFE surface. The magnitude of the fibrin
coating (f) is distorted by the preparation of the specimen for
microscopy. (Original magnification 4000×.)
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branch of the circumflex artery in 5 patients, the cir-
cumflex artery itself in 2 patients, and the right coro-
nary artery (RCA) in 9 patients. In 2 patients an addi-
tional saphenous vein graft was used to revascularize
the ramus intermedius and the first marginal branch. In
12 of the 14 patients, the postoperative recovery was
free of complications. One patient receiving a redo pro-
cedure with the left ITA to the LAD and an EC-seeded
PTFE bypass to the RCA died 4 weeks postoperatively
of multiorgan failure after pneumonia. One patient had
a perioperative myocardial infarction caused by the
immediate failure and occlusion of the EC-seeded
PTFE graft to the distal RCA because of poor runoff
and possible contamination of the EC culture with
fibroblasts, as proven by a re-evaluation of the cell cul-
ture. All other patients are still alive and out of the hos-
pital. They are free of angina pectoris, and none had a
myocardial infarction. Between 7.5 and 48 months
(median, 29.5 months) after the bypass operation, 19
(90.5%) of 21 EC-seeded PTFE grafts for coronary
artery bypass in 14 patients were patent. In patient 2 the
EC-seeded PTFE graft bypassing the RCA is asympto-
matically occluded, which was verified by means of
routine coronary reangiography 20.5 months after the
operation. Selective angiography of the EC-seeded
PTFE grafts demonstrates a smooth luminal border of
the grafts without stenotic regions (Fig 4). Selective
angioscopic evaluation of the EC-seeded PTFE pros-
theses of the patients shows a glossy white lumen of the
graft with a smooth luminal surface without any fibrin,
platelet, or erythrocyte deposits on the luminal wall
(Fig 5). By means of intravascular ultrasound (Fig 6),
the smooth unobstructed luminal surface of the grafts
could be confirmed.
Table II.  Demographics, performed procedures, and outcomes of the patients who received EC-seeded PTFE
grafts for coronary artery bypass
Patient  No. Bypasses/ EC-seeded 4-mm 
(sex, age[y]) Diagnosis Operation additional procedures PTFE graft Follow-up
1 3-vessel CAD, CABG II LITA → LAD M1 (PTFE)† Patent at 48 mo
(M, 71) postthrombotic syndrome
2 2-vessel CAD, CABG II LITA → LAD RCA (PTFE)‡ Asymptomatic occlusion
(M, 69) postthrombotic syndrome after 20.5 mo
3 3-vessel CAD, CABG III LITA → LAD, RCX (PTFE)‡ Patent at  45.0 mo
(F, 73) varicosis SVG → RIM
4 3-vessel CAD, CABG III LITA → LAD M1-RCA, horseshoe Patent at 37.0 mo
(M, 78) postthrombotic syndrome jump (PTFE)‡
5 3-vessel CAD, CABG III LITA → LAD RIM (PTFE)† Patent at 34.0 mo
(M, 64) varicosis
6 3-vessel CAD, CABG II LITA → LAD, Distal RCA Patent at 34.0 mo
(M, 62) varicosis SVG → M1 (PTFE)‡
7 Redo 2-vessel CAD, Redo CABG II, 29-mm SJM Toronto LAD-RCA, horseshoe Patent at 29.5 mo
(M, 71) aortic stenosis AVR SPV xenograft* jump (PTFE)‡
8 Redo 2-vessel CAD, Redo CABG II D1, M1; single Patent at 29.5 mo
(M, 66) CABG III (1992) (PTFE)‡
9 Redo 2-vessel  CAD, Redo CABG II M1, distal RCA; Multiorgan failure
(M, 61) CABG II (1992) occluded single (PTFE)‡ 4 wk postop
10 Redo 3-vessel CAD, Redo  CABG II LITA → LAD M1 (PTFE)‡ Patent at 23.0 mo
(M, 72) CABG III (1985) occluded
11 3-vessel CAD, CABG III LITA → LAD, RCA (PTFE)‡ Patent at 18.0 mo
(F, 73) varicosis free RITA → RCX
12 Redo 3-vessel CAD, Redo CABG III LITA → LAD D1, distal RCA, Patent at 17.0 mo
(M, 64) CABG II (1991) single (PTFE)‡
13 Redo 2-vessel CAD, Redo  CABG II RCX-RCA, horseshoe Patent at 10.0 mo
(M, 75) CABG I (1986) jump (PTFE)‡
14 3-vessel CAD, CABG III LITA → LAD RCA, D1 Patent at 7.5 mo
(M, 79) varicosis single (PTFE)‡
AVR, Aortic valve replacement; CABG, coronary artery bypass graft; CAD, coronary artery disease; D1, first diagonal branch; LITA, left internal thoracic artery; M1,
first marginal branch; RCX, right circumflex; RIM, ramus intermedius; RITA, right internal thoracic artery; SVG, saphenous vein graft.
*St Jude Medical, Inc, St Paul, Minn.
†Mediflex vascular graft; Medino GmbH, Gehrden, Germany.
‡Gore-Tex vascular graft; W. L. Gore & Associates, Inc, Flagstaff, Ariz.
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Discussion
This is the first clinical report about autologous EC-
seeded 4-mm PTFE vascular grafts used for coronary
artery bypass grafting. In a mean of 27.7 months
(range, 7.5-48 months) after the operation, 90.5%
(19/21) of the autologous EC-seeded 4-mm PTFE
grafts are patent and show an improved patency com-
pared with the unseeded PTFE prostheses with patency
rates of 59% to 64.3% after 12 months.16,17 To deter-
mine whether long-term patency of autologous EC-
seeded PTFE grafts surpasses the patency of saphenous
vein grafts will require a larger number of patients and
a prolonged period of follow-up investigations. After
10 years, the patency of saphenous vein grafts used as
coronary bypass conduits declines to 60% to 70%.18,19
It is encouraging that the good patency of the EC-seed-
ed PTFE grafts is achieved without anticoagulation of
the patients postoperatively. All patients received only
an antiplatelet medication with 100 mg of acetylsali-
cylic acid per day. Selective angiographic, angioscopic,
and intravascular ultrasonographic evaluations of the
patients up to 48 months postoperatively showed a very
smooth and glossy luminal graft surface, which implies
indirectly a very biocompatible graft surface naturally
Fig 4.  Selective angiography of autologous EC-seeded 4-mm PTFE grafts as coronary bypass. A, Twelve months
postoperatively (patient 1); B, 45 months postoperatively (patient 1); C, 24 months postoperatively (patient 7).
A B
C
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provided by autologous ECs, as demonstrated in Figs 5
and 6. In vitro flow experiments with endoluminal
seeded 4-mm PTFE grafts with indium-[111In]-oxin
labeled vital human ECs revealed only a washout of
ECs between 10% and 15% in the first minute after the
installation of a physiologic pulsatile flow. Dependent
on different flow conditions, 69% to 83% of the vital
seeded ECs adhered permanently to the luminal graft
wall,20,21 supporting the hypothesis that the ECs adhere
and can survive in the long term. An endoluminal vital
confluent monolayer of autologous ECs reduces the
thrombogeneity of the PTFE graft and increases the
Fig 5.  Selective intravital angioscopy of autologous EC-seeded 4-mm PTFE grafts as coronary bypass grafts
(Baxter angioscope with 1-mm tip). A, Twelve months postoperatively (patient 1); B, 24 months postoperatively
(patient 7).
Fig 6. Intravital intravascular ultrasonography of autologous EC-seeded 4-mm PTFE grafts as coronary bypass
grafts. A, Forty-five months postoperatively (patient 1); B, 18 months postoperatively (patient 10). A small arte-
riosclerotic plaque is marked by the arrow.
A B
A B
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patency of 4-mm PTFE vascular grafts for coronary
artery bypass compared with unseeded grafts.16,17
Similar results were published by Zilla and col-
leagues22 in 1994. They reported that EC-seeded 6-mm
PTFE vascular prostheses have a much better patency
rate than unseeded PTFE grafts for femoropopliteal
reconstruction in peripheral vascular occlusive disease
with a follow-up of more than 3 years. In one case
Deutsch and colleagues23 could demonstrate 41 months
after the implantation of an autologous EC-seeded 6-
mm PTFE graft for revascularization of the lower limb
that a vital confluent EC monolayer still covered the
lumen of the PTFE prosthesis, which indicates that in
vitro vital EC seeding of PTFE grafts leads to a stable
luminal EC lining.
The ITA is undoubtedly the coronary bypass graft of
first choice, with a patency of over 90% after 10
years.18,19 The gastroepiploic artery is also superior,
with a patency rate of 94% 24 to 60 months after the
operation.24 The inferior epigastric artery, with a paten-
cy of 90% after 12 months,25 and the radial artery, used
as a free graft with 88% patency as a coronary artery
bypass graft 12 months after the operation,25 seem of
equal quality compared with EC-seeded PTFE. The
cephalic vein, with 47% patency after 54 months’ fol-
low-up,26 shows a much poorer patency rate when
compared with the autologous EC-seeded PTFE coro-
nary bypass graft. Even worse are the patencies of
cryopreserved homologous saphenous vein grafts (41%
after 7 months)27 and the bovine ITA (14% 1 year after
the operation).28
Conclusions
Autologous EC seeding increases the biocompatibil-
ity of 4-mm PTFE coronary artery bypass grafts.
Autologous EC-seeded 4-mm PTFE bypasses are an
alternative as coronary artery bypass for patients with
insufficient saphenous vein graft bypass material in
elective coronary artery bypass operations who are not
candidates for complete arterial revascularization.
We thank Mrs Nickel for excellent technical assistance in
the laboratory and in the cell culture work.
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